Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy

• Published in: Journal of endocrinological investigation 2024-10, Vol.47 (10), p.2615-2621
• Main Authors: Gosmanov, A. R., Gemoets, D. E., Schumacher, K. A.
• Format: Article
• Language: English
• Subjects: Aged; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Drug Therapy, Combination - adverse effects; Endocrinology; Hematocrit; Hormone Replacement Therapy - adverse effects; Hormone Replacement Therapy - methods; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Original Article; Polycythemia - chemically induced; Polycythemia - epidemiology; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors - administration & dosage; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Testosterone - administration & dosage; Testosterone - adverse effects; Testosterone - blood
• ISSN: 1720-8386; 1720-8386
• DOI: 10.1007/s40618-024-02350-1

Purpose In clinical trials, sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and testosterone replacement therapy (TRT) were shown to stimulate red blood cell production. Little is known if combination therapy poses risk of erythrocytosis in real world clinical practice. Methods This was a retrospective nationwide cohort study of US Veterans with type 2 diabetes (T2D) and baseline hematocrit between 38 and 50% who were prescribed SGLT-2i and/or TRT between 3/2013 and 10/2022 and had adequate adherence based on the proportion of days covered > 80%. Patients were divided into 3 groups: SGLT-2i only, TRT only, or combination therapy. Odds Ratio (OR) of new erythrocytosis defined as hematocrit level > 54% within 365 days of therapy initiation was calculated by logistic regression model adjusted for baseline hematocrit, age, BMI, obstructive sleep apnea, diuretic use, and smoking status. Results Of the entire cohort of 53,971 people with T2D, total of 756 (1.4%) patients developed erythrocytosis. In unadjusted analyses, the OR of new onset erythrocytosis was higher in the combined SGLT-2i and TRT group compared with the SGLT-2i or TRT group alone (4.99, 95% CI (3.10–7.71) and 2.91, 95% CI (1.87–4.31), respectively). In the models adjusted for baseline characteristics, patients on combination therapy had significantly higher odds of erythrocytosis compared to those on SGLT-2i (OR 3.80, 95% CI (2.27–6.11)) or TRT alone (OR 2.49, 95% CI (1.51–3.59)). Testosterone delivery route (topical vs injectable) did not modify increased odds of erythrocytosis. Conclusions For the first time, we demonstrated that in large cohort of patients combined therapy with SGLT-2i and TRT is associated with increased erythrocytosis risk compared with either treatment alone. Given rising prevalence of SGLT-2i use, providers should consider periodic hematocrit assessment in persons receiving both SGLT-2i and TRT.